Nicola Curtin

Professor Nicola Curtin is a leading academic at Newcastle University specializing in DNA damage response and cancer therapeutics. Her research focuses on developing inhibitors targeting key DNA repair enzymes like PARP, ATR, and DNA-PK to enhance cancer treatment efficacy. She has pioneered studies on synthetic lethality approaches, particularly in BRCA-deficient cancers, and explored drug repurposing for viral infections like COVID-19.

Her work spans multiple oncology domains: investigating PARP inhibitor mechanisms, chemosensitization strategies, DDR pathway modulation, and biomarker development. Research integrates molecular biology techniques with preclinical models to validate therapeutic concepts, emphasizing translational potential. Key interests include overcoming therapy resistance and developing combinatorial regimens.

Publications demonstrate consistent focus on DNA repair targeting across solid tumors, with recent expansion into virology. Article analysis reveals three major themes: 1) Mechanistic studies of PARP/ATR inhibitors, 2) Synthetic lethality applications, and 3) Therapeutic repurposing for non-oncological conditions. Collaborative work frequently involves biomarker validation and resistance mechanism elucidation.

No awards or student advisees are detailed in the source material. Research outputs indicate leadership in multinational consortia focused on DDR inhibitors and frequent industry-academia partnerships for therapeutic development.